An Overview of NanoCluster Powder Formulation Technology - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

An Overview of NanoCluster Powder Formulation Technology
The authors describe a technique designed to yield low-density powders with a tailored particle-size distribution over a broad range of respiratory flow rates.

Pharmaceutical Technology
Volume 10, Issue 34, pp. 72-78

Device requirements

Figure 4: Comparison of Pulmicort Respule (AstraZeneca, London) and budesonide NanoCluster (Savara Pharmaceuticals, Austin, TX) performance by the LC Plus nebulizer (PARI, Midlothian, VA). The authors used an Andersen cascade impactor with a rate of 30 L/min at 25 C and 45% relative humidity.
The particle size, shape, and performance characteristics of NanoCluster powders enable effective drug delivery through various inhalation devices. Several studies and evaluations have demonstrated that NanoCluster formulations provide emitted doses with high fine-particle fractions, even when delivered with simple, nonproprietary dry-powder devices such as the Monodose (Plastiape, Osnago, Italy), Turbuhaler (AstraZeneca, London), Easyhaler (Orion Pharma, Espoo, Finland), and Accuhaler (GlaxoSmithKline, London). When suspended in water and administered by nebulization, these formulations exhibit excellent delivery performance (see Figure 4). Studies with NanoCluster formulations delivered through pMDIs are currently ongoing to confirm the formulations' performance in this device class. The NanoCluster technology reduces the need for complex, expensive delivery devices to achieve repeatable aerosol delivery appropriate for deep lung deposition.


Savara's NanoCluster technology enables high-performance powder formulations that offer the opportunity to improve the performance of inhalation products significantly for local and systemic therapy. NanoCluster manufacturing processes are not complex and use common equipment and accepted pharmaceutical processes. NanoCluster formulations help companies optimize the aerodynamic properties of drug products, reduce the need for complex delivery devices, and improve safety and, potentially, efficacy. The relative simplicity and adaptability of the NanoCluster technology provides a cost-effective formulation platform that can shorten the development timelines of inhalation products.

Cory Berkland* is an associate professor of chemical and petroleum engineering and of pharmaceutical chemistry at the University of Kansas, 4141B Learned Hall, 1530 W. 15th St., Lawrence, KS 66045, tel. 785.864.1455, fax 785.864.4967,
Stephen Lermer is a partner at AlphaVektor Consulting. George Laurence is founder, Pravin Soni is head of chemistry, manufacturing, and controls, and Michael Crowley is president of Theridian Technologies, all at Savara Pharmaceuticals.

*To whom all correspondence should be addressed.

Submitted: Sept. 24, 2009. Accepted: Feb. 1, 2010.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here